Brain dysfunction, especially cognitive impairment, is one of the main complications in Alzheimer's disease (AD), which threatens the health of 46.8 million people worldwide. At present, the pathogenesis of cognitive dysfunction is only partially understood, and effective therapies for memory loss in AD remain elusive. Tetramethylpyrazine (TMP) is one of the major bioactive compounds purified from Chuanxiong, a Chinese herb used for the treatment of neurovascular and cardiovascular diseases. The neuroprotective properties of TMP are evident in some neurodegenerative diseases, including Parkinson's disease. However, whether TMP plays a neuroprotective role in AD is still unknown. Here, we report that 2-week treatment with TMP rescued both shortterm and long-term fear memory impairment induced by intracerebroventricular injection of streptozotocin in a well-known AD rat model. Administration of TMP also restored spatial learning and memory retention abilities in streptozotocin-injected rats. Furthermore, TMP inhibited the activity of GSK-3β, an important kinase that mediates hippocampal synaptic and memory disorders in diabetes mellitus. Finally, we found that TMP treatment restored the function of cholinergic neurons. Our data suggest that dietary uptake of TMP can provide protection against memory loss in AD, and the inhibition of GSK-3β may play an important role in this protective effect.
Introduction
Alzheimer's disease (AD) is an aging-dependent, progressive neurodegenerative disorder, clinically characterized by dysfunction in memory and cognition. The neuropathological hallmarks of AD include deposition of insoluble fibrillar amyloid β peptide (Aβ) in extracellular plaques and aggregated tau protein, which is found largely in intracellular neurofibrillary tangles [1] . Although the precise mechanisms for AD are not clear, decreasing brain glucose consumption has been reported as a very early sign of the disease. For example, measurements using the 18 FDG-PET technique in individuals harboring AD genes have shown that signs of depressed brain glucose uptake, apparently independent of structural atrophy, are detectable up to three decades prior to the expected onset of clinical symptoms of early onset familial AD [2] . Because AD brains present features of impaired insulin signaling and single or double intracerebroventricular (icv) streptozotocin (STZ) injection(s) chronically decrease cerebral glucose uptake and produce many other effects resembling the molecular, pathological, and behavioral features of AD, icv STZ injections are exploited by some investigators as a nontransgenic model for AD and are used for preclinical testing of pharmacological therapies [3] . Traditional Chinese medicine has been widely applied in China for more than 2000 years. Many active pharmacological compounds from Chinese herbal medicines have been identified for the treatment of various neurological diseases. In recent years, scientists have isolated many novel compounds from herbs, some of which improve dementia with fewer side effects than conventional drugs and are regarded as potential anti-AD drugs [4] . Tetramethylpyrazine (TMP) is one of the most important active ingredients of the Chinese herb Ligusticum wallichii Franch (chuanxiong Hort). TMP exhibits diverse biological activities, such as inhibiting platelet aggregation, lysing blood clots, blocking calcium entry, inhibiting cell apoptosis, and scavenging free radicals [5] . The neuroprotective effects of TMP were identified in cerebral ischemic damage in models of global and focal cerebral ischemia [6] [7] [8] . TMP has been demonstrated to increase cerebral blood flow [9] , improve microcirculation, and reduce capillary permeability [10] . TMP also protects learning and memory functions and rescues cholinergic dysfunction in D-galactose-lesioned mice [11] . However, the ability of TMP to rescue STZ-induced memory deficits and the possible underlying mechanisms are not clear.
In this study, we attempted to clarify the effects of TMP on STZinduced memory deficits and to explore the potential underlying mechanisms. We showed that TMP application reversed STZ-induced memory impairment in both inhibitory avoidance tasks and the Morris water maze task, which rely on the normal function of the hippocampus [12] , the important brain region for learning and memory [13] . TMP also inhibited the activation of GSK-3β and restored cholinergic neuronal function.
Materials and Methods

Drugs and antibodies
TMP and STZ were obtained from Sigma (St Louis, USA). Polyclonal antibodies anti-total GSK-3β and anti-phospho-GSK-3β (phosphorylated at Ser9; pS9-GSK-3β) were obtained from Bioworld Technology Inc. (St Louis Park, USA). Commercial kits were used to assay the level of ACh and the activity levels of cholineacetyltransferase (ChAT) and acetylcholinesterase (AChE; Nanjing Jiancheng Biotech, Inc., Nanjing, China). IRDye 800CW-conjugated goat (polyclonal) anti-rabbit IgG (1:10,000) and IRDye 800CW-conjugated goat (polyclonal) anti-mouse IgG (1:10,000) were purchased from LI-COR Biosciences (Lincoln, USA).
Animals
Forty-eight male Wistar rats (250 ± 10 g, 3 months old) were purchased from the Laboratory Animal Center of Zhengzhou University. All animal experimental protocols were approved by Care and Use of Laboratory Animals of Henan Province. The rats were housed in polypropylene cages in a vivarium at room temperature under a 12/12-h light/dark cycle (lights on at 8:00 am) and with access to food and water. Animals were first acclimatized to the facility for 5 days and then randomly divided into four groups: a control group receiving vehicle in a volume of 5 μl of citrate buffer on days 1 and 3 (control, n = 12), a group receiving bilateral injections of 5 μl of 3 mg/kg STZ on days 1 and 3 (STZ, n = 12), a group receiving STZ as well as TMP (20 mg/kg/d, ip) pretreatment for 2 weeks (TMP+STZ, n = 12), and a TMP single administration group (TMP, n = 12).
Brain surgery
The rats were anesthetized with 10% chloral hydrate (6 ml/kg, ip) and fixed on the stereotaxic apparatus. Two burr holes were drilled through the exposed skull and icv cannulas were placed bilaterally using the following coordinates: 0.8 mm posterior to bregma, 1.5 mm lateral to the sagittal suture, and 3.6 mm ventral [14, 15] from the surface of the brain; they were then fixed with dental cement. Once-daily gentamicin (5 mg/kg, ip) was injected following surgery, and antiseptic powder (Neosporin) was applied at the site of the cut to prevent sepsis. Motor activity was assessed before and 72 h after surgery, and animals with similar pre-and post-surgery values and without blood clots in the icv cannulas were selected and used in the study. Animals underwent behavioral tasks the following week. The complete experimental procedure is shown in Fig. 1 .
Inhibitory avoidance task assay
The inhibitory avoidance apparatus was an acrylic box (50 cm × 25 cm × 25 cm), with a floor consisting of parallel stainless steel bars (1 mm in diameter) spaced 1 cm apart. A platform (7 cm in width, 3 cm in height) was placed in the corner. The animals were placed on the platform, and their latency to step down onto the grid with all four paws was measured with an automatic device. The double-blinded inhibitory avoidance task was performed by using a protocol similar to that described previously [16] . During training sessions, animals received a 0.4-mA, 1.0-s scrambled foot shock immediately after stepping down onto the grid. During test sessions, no foot shock was administered, and the step-down latency (maximum 180 s) was used to measure retention. The animals underwent a single training session. In order to evaluate short-term memory (STM) and long-term memory (LTM), test sessions were performed 1.5 and 24 h after training, respectively [17, 18] .
Morris water maze assay
Spatial learning and memory were tested in a Morris water maze [19, 20] . The maze consisted of a circular water tank (180 cm in diameter, 60 cm in height) filled with water (20-21°C) to a depth of 40 cm and divided into four imaginary quadrants (NE, NW, SE, and SW). Briefly, the rats were trained over 5 days to find a platform in the SE quadrant that was submerged in 1-2 cm of water by using a stationary array of cues outside the pool. In each trial, rats were given a maximum of 60 s to find the hidden platform and were allowed to remain on it for 30 s. Acquisition training consisted of a total of 20 trials, with 4 spaced trials per day for 5 consecutive days. After 1 day of rest, a probe trial was performed, during which the platform was removed. The percentage of time spent in the target quadrant, crossing times, and swimming pathways were recorded. During the entire task, swimming speed was analyzed to evaluate motor ability. 
Western blot analysis
Following behavioral testing, six rats from each group were used for biochemical assays. After the rats were sacrificed, the hippocampus on the left side was removed and homogenized in buffer containing 10 mM Tris-HCl, pH 7.6, 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM edetic acid, 1 mM benzamidine, and 1 mM phenylmethylsulfonyl fluoride (PMSF). The supernatants were transferred to new Eppendorf tubes. Total protein concentration was determined using the BCA Kit. For western blot detection, a final concentration of 5% β-mercaptoethanol and 0.05% bromophenol blue was added, and the samples were boiled for 10 min. Equal amounts of proteins were isolated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. The membranes were blocked in 5% nonfat milk and probed with antibodies for total GSK-3β, pS9-GSK-3β, and β-actin overnight at 4°C. Membranes were then rinsed three times, incubated with secondary antibodies for 2 h at room temperature, and visualized using the Odyssey Infrared Imaging System (LICOR Bioscience Inc., Lincoln, USA). Protein bands were quantitatively analyzed by Kodak Digital Science 1D software (Eastman Kodak Company, New Haven, USA).
Analysis of cholinergic function
The hippocampus on the right side was weighed and homogenized in nine volumes of 0.1 M phosphate buffer (pH 7.4), and the homogenate was centrifuged at 1000 g for 10 min at 4°C. The supernatant was diluted with an appropriate buffer solution for analysis of cholinergic function, and ChAT and AChE activity was measured spectrophotometrically using the corresponding assay kits according to the manufacturer's instructions. The level of ACh in the hippocampal supernatant was detected with the ELISA kit according to the manufacturer's instructions.
Statistical analysis
All statistical analyses were conducted using SPSS version 13.0. Group differences in escape latency in the Morris water maze task were analyzed using two-way analysis of variance (ANOVA) with repeated measures, with group (treatment) and time (testing day) as factors. Otherwise, data were analyzed by one-way ANOVA followed by the Student-Newman-Keuls (SNK) test as a post hoc test. Significance was set at P < 0.05 for all tests.
Results
Different treatment does not alter physiological parameters
Physiological parameters of rats in different groups are presented in Table 1 , including body weight (both pretreatment and posttreatment), respiratory frequency, and body temperature. It was found that although the body weights of every group increased about 5% on the day the rats were sacrificed, there was no significant difference among the four groups. All groups showed similar respiratory frequency and body temperature throughout the experimental procedure. These results suggest that TMP does not affect the baseline physiological function.
TMP reverses LTM deficits of STZ-treated rats
To examine whether TMP pretreatment could rescue memory deficits in STZ rats, STM and LTM were first detected using the inhibitory avoidance task after the motor ability assay by vertical pole test, which didn't find any differences among four groups ( Supplementary Fig. S1 ). Rats were subject to one session of stepdown inhibitory avoidance training 24 h after drug administration. STM and LTM were then measured 1.5 and 24 h after training (Fig. 2) . Two-way repeated measures ANOVA showed a significant time course effect (F (2,9) = 16.77, P < 0.05) and different treatment effect (F (3,140) = 7.33, P < 0.05) in inhibitory avoidance, while the interaction between time course and treatment was not significant (F (3,140) = 0.97, P > 0.05). It was found that STZ significantly decreased the latency in the STM test (F (3,44) = 6.26, P < 0.05) but not in training (F (3,44) = 2.53, P > 0.05). In the LTM test, STZ infusion significantly decreased the latency (F (1,22) = 14.53, P < 0.01) compared with that in controls, and pretreatment with TMP not only reduced the prolonged latency by STZ (F (1,22) = 9.13, P < 0.05) but also shortened the background latency (F (1,22) = 7.18, P < 0.05) in the LTM test compared with the latencies of the control group. These data suggest that TMP can reverse long-term fear memory deficits in STZ-treated rats.
TMP protects against impairments of spatial learning and memory in STZ-treated rats
In the Morris water maze task, icv STZ-treated rats showed poor learning abilities during the acquisition trial (Fig. 3A) . Significant reductions were found in escape latency time with progressive training (two-way repeated measures ANOVA; F (3,44) = 56.39, P < 0.001 for different group; F (4,235) = 14.25, P < 0.01 for time; and F (12,235) = 1.63, P = 0.140 for interaction). During the training period, there were no significant differences between the mean latencies of all groups on days 1 and 2, but the mean latencies were found to be significantly prolonged on days 3-5 (F (1,22) = 14.25, P < 0.01) in the STZ-treated rats as compared with those of vehicle control rats, indicating their inability to learn the task. However, the STZinduced acquisition deficit was significantly attenuated by chronic treatment with TMP (F (1,22) = 7.48, P < 0.05). Similar results were also obtained in the retention trial (probe trial, Fig. 3B,C) . STZtreated rats failed to remember the precise location of the platform and spent significantly less time in the target quadrant (F (1, 22) = 10.88, P < 0.01) and showed fewer crossing times (F (1, 22) = 5.96, P < 0.05) than the vehicle control group. However, STZ-induced learning and memory deficits were significantly attenuated by TMP treatment, and rats were able to identify the precise location of the platform and spend more time in the target quadrant (F (1, 22) = 13.64, P < 0.01). Similar to earlier observations, single administration of TMP also improved the performance of rats in the Morris water maze task (F (1, 22) = 6.47, P < 0.05).
TMP reverses STZ-induced GSK-3β activation in hippocampus
The levels of total GSK-3β and pS9-GSK-3β in the hippocampus of rats were detected by western blot analysis (Fig. 4A,B) . Quantitative analysis of the p-GSK-3β/GSK-3β ratio showed that pS9-GSK-3β (the inactivated form) level in the hippocampus was significantly decreased (F (1,22) = 9.58, P < 0.01) in the STZ group in comparison with that in the control group, indicating that hippocampal GSK-3β was activated after STZ treatment. TMP pretreatment significantly enhanced GSK-3β phosphorylation in comparison to that in STZ and control groups (F (1,22) = 7.59, P < 0.05, respectively). Total GSK-3β levels did not show significant differences between these groups. A further kinase activity analysis verified the inhibition of GSK-3β by TMP (Fig. 4C) .
TMP rescues cholinergic dysfunction in STZ rats
We then measured the effect of STZ and/or TMP on ACh level and AChE and ChAT activities in the hippocampus of rats. As shown in Fig. 5 , STZ caused a significant decrease in ACh level (control, 145.11 ± 8.12 nmol/g; STZ, 80.42 ± 6.13 nmol/g; F (3,44) = 101.12, P < 0.01), an increase in AChE activity (control, 0.71 ± 0.03 U/mg protein; STZ, 0.92 ± 0.11 U/mg protein; F (3,44) = 34.25, P < 0.01), and a dramatic reduction in ChAT activity (control, 318.70 ± 14.32 U/mg protein; STZ, 274.10 ± 8.02 U/mg protein; F (3,44) = 49.58, P < 0.01) in the hippocampus. These results verified that STZ impairs cholinergic function. Expectedly, the administration of TMP in STZ rats was The ratio of pS9-GSK-3β/GSK-3β was calculated. (C) The activity of GSK-3β was measured by ELISA. n = 6. *P < 0.05, **P < 0.01 vs. control group; # P < 0.05, ## P < 0.01 vs. STZ group. Figure 5 . TMP restores cholinergic system functions After the behavioral test, the cholinergic system function in the hippocampus was assayed using ACh (A), AChE (B), and ChAT (C) kits (n = 12). *P < 0.05, **P < 0.01 vs. control group; # P < 0.05, ## P < 0.01 vs. STZ group.
able to rescue these cholinergic abnormalities, as indicated by elevated ACh level (112.60 ± 7.33 nmol/g, P < 0.01), increased ChAT activity (301.41 ± 21.50 U/mg protein, P < 0.01), and reduced AChE activity (0.73 ± 0.11 U/mg protein, P < 0.01). Single administration of TMP did not alter ACh levels. These data support the behavioral test results and suggest that TMP may exert its neuroprotective effects by rescuing cholinergic function.
Discussion
TMP is a biologically active ingredient that was first extracted from the Chinese medicinal plant Ligusticum wallichii Franch (chuanxiong Hort), which has been widely used to treat many neurological diseases, such as ischemic cerebral vascular disorder [21] and Parkinson's disease [22] . In the present study, we investigated the protective effect of TMP on memory impairments and cholinergic neuron dysfunction, elucidating possible mechanisms in AD rats.
In our study, we chose a stereotaxic bilateral injection of STZ into the icv space in rats, which is considered a good model for the early stage of AD [3] . Using this AD rat model, we evaluated the protective effect of TMP against STZ-induced memory impairments. We showed that TMP could significantly prevent STZ-induced learning and memory deficits, reflected by improvement in the inhibitory avoidance and Morris water maze tasks. Several studies have shown that the icv STZ rodent model displays similar biochemical and immunohistochemical alterations as those in the brains of a transgenic and a non-transgenic murine model of AD, 3xTg-AD mice [23, 24] . Moreover, icv STZ injection exacerbates memory disturbances and AD-like neurochemical changes in the brains of 3xTg-AD mice [25] , further indicating that icv STZ is a good sporadic AD model. In this study, we found that STZ caused spatial memory and fear memory impairments (Figs. 2 and  3) , indicating a deficit in learning ability, a well-known characteristic of AD. We also showed that TMP inhibited the activity of GSK-3β and restored the function of cholinergic neurons. These results suggest that TMP exhibits protective effects against memory loss and cholinergic toxicity induced by STZ.
In the brains of adult icv STZ-treated rats, Deng et al. [23] found impaired insulin signaling and overactivation of GSK-3β. The key mechanism in the development of the disease in humans, as well as in the rodent model, is the development of brain insulin resistance, which leads to neurofibrillary degeneration. GSK-3β is a constitutively active, proline-directed serine/threonine kinase that plays important roles in multiple cellular processes, and its dysregulation is implicated in the pathogenesis of diverse diseases, including both sporadic and familial forms of AD [26, 27] . Activation of GSK-3β accounts for memory impairment, tau hyperphosphorylation, increased Aβ production, and local plaque-associated microglial-mediated inflammatory responses, all of which are hallmark characteristics of AD [28] . Here, we found that TMP is able to inhibit the activity of GSK-3β by promoting the inhibitory Ser9 phosphorylation. In another two previous studies, TMP was shown to decrease GSK-3β expression at both protein and RNA levels [29] , and its analogue CXC195 could protect against cerebral ischemia/reperfusion-induced apoptosis through the PI3K/Akt/GSK-3β pathway [30] . In a rat model of spinal cord injury (SCI), the neuroprotection of TMP is mediated by the activation of Akt [31] . In SH-SY5Y cells, TMP was shown to promote the cell differentiation toward the neuronal phenotype through activation of the PI3K/Akt, the upstream of GSK-3β [32] . Here, we found that TMP treatment enhances the phosphorylation of Ser9 in GSK-3β but does not reduce the protein level of GSK-3β, suggesting that some upstream regulators, such as PI3K/Akt are involved. Interestingly, TMP treatment increased the phosphorylation of Ser9 of GSK-3β but did not change the activity of GSK-3β in normal rats. As the activity of GSK-3β can be regulated by multiple mechanisms [33] , we propose that some other regulatory mechanisms might be involved in the GSK-3β regulation by TMP in normal rats. Given the important role of Akt/GSK-3β in memory processes, our study implies that the Akt/GSK-3β pathway may play a role in the neuroprotective effects of TMP on the memory deficits induced by STZ.
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